Clinical Efficacy of Transarterial Infusion Chemotherapy for Unresectable Colorectal Cancer

Summary

This is a prospective, multicenter, randomized, and open-label clinical trial. It is initiated to determine the efficacy of FOLFOX-based, transarterial infusion chemotherapy (TAIC) combined with either cetuximab or bevacizumab for patients with unresectable colorectal cancer (CRC).

Conditions

• Unresectable Colorectal Cancer

Interventions

PROCEDURE

Transarterial infusion chemotherapy (TAIC)

TAIC can increase the local intra-tumoral concentrations of chemotherapeutic agents by intensifying drug delivery into the tumor via super-selective catheterization of the tumor-feeding artery, and meanwhile reduce systematic toxicity.

PROCEDURE

Intravenous Chemotherapy（IVC）

Intravenous administration of chemotherapeutic agents is the mainstay of chemotherapy.

Sponsors & Collaborators

• Liaoning Cancer Hospital & Institute

  collaborator OTHER

• The Rocket Force Characteristic Medical Center

  collaborator UNKNOWN

• Second Affiliated Hospital of Nanchang University

  collaborator OTHER

• The Affiliated Hospital of Hebei University

  collaborator UNKNOWN

• The First Hospital of Qinhuangdao

  collaborator OTHER_GOV

• The Central Hospital of Handan City

  collaborator UNKNOWN

• The First People's Hospital of Jiujiang City

  collaborator UNKNOWN

• Changzhi Medical College

  collaborator OTHER

• Zibo Boshan District Traditional Chinese Medicine Hospital

  collaborator UNKNOWN

• Linshu County People's Hospital

  collaborator UNKNOWN

• Hebei Yixian Hospital

  collaborator UNKNOWN

• Baoding Mancheng District People's Hospital

  collaborator UNKNOWN

• Quanda Liu

  lead OTHER

Principal Investigators

• Quanda Liu, MD · Guang'anmen Hospital of China Academy of Chinese Medical Sciences

Study Design

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Model

PARALLEL

Eligibility

Min Age

18 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2026-03-31

Primary Completion

2027-12-31

Completion

2027-12-31

Countries

• China